- Conditions
- Primary Ciliary Dyskinesia, Kartagener Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Not listed
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Aurora, Colorado • Indianapolis, Indiana + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2521–2544
of 11,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Folliculogenesis
- Interventions
- elagolix
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 20
- States / cities
- Colorado Springs, Colorado • Denver, Colorado • Lonetree, Colorado + 14 more
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma
- Interventions
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Drug
- Lead sponsor
- Cellectar Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Redlands, California • Washington D.C., District of Columbia + 25 more
- Conditions
- HSV-2
- Interventions
- AIC316, Placebo
- Drug
- Lead sponsor
- AiCuris Anti-infective Cures AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Miami, Florida • Indianapolis, Indiana • Portland, Oregon + 3 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
- Interventions
- Best Practice, Biopsy of Breast, Computed Tomography, Electronic Health Record Review, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Immune Checkpoint Inhibitor, Poly (ADP-Ribose) Polymerase Inhibitor, Positron Emission Tomography
- Other · Procedure · Radiation + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Umbralisib
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 15
- States / cities
- Huntsville, Alabama • Washington D.C., District of Columbia • Fort Myers, Florida + 12 more
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure,Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
- Interventions
- CardioMEMS™ HF System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 125
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
- Conditions
- Chronic Hepatitis B, Hepatitis B, Chronic
- Interventions
- Bepirovirsen, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 857 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 12
- States / cities
- Centreville, Alabama • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 58
- States / cities
- Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more
- Conditions
- Cognitive Impairment, Malignant Neoplasm
- Interventions
- Ibuprofen, Placebo, Questionnaire Administration
- Drug · Other
- Lead sponsor
- University of Rochester NCORP Research Base
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 169
- States / cities
- Burbank, California • Lewes, Delaware • Newark, Delaware + 99 more
- Conditions
- Healthy
- Interventions
- Education and self-efficacy coaching
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 334 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
- Interventions
- Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- Not listed
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Los Angeles, California • Harvey, Illinois + 4 more
- Conditions
- Acute Liver Failure, Hepatic Encephalopathy
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2015
- U.S. locations
- 17
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 13 more
- Conditions
- Hospitalized Child, Pediatric Patient Safety, Medical Errors, Parental Engagement in Care, Inpatient Pediatric Care
- Interventions
- Access to medical notes
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Seattle, Washington • Madison, Wisconsin
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
- Interventions
- Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Post-Transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient Reported Outcomes, Melphalan, Total-body irradiation, Cyclophosphamide
- Drug · Procedure · Other + 1 more
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
- Conditions
- Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
- Interventions
- APR-246, Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
- Drug
- Lead sponsor
- Aprea Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 9 more
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
- Interventions
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Drug · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 17
- States / cities
- Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more
- Conditions
- Cholestasis
- Interventions
- Intralipid 20% I.V. Fat Emulsion
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 2 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Durvalumab + SoC chemotherapy, Placebo + SoC chemotherapy
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Long Beach, California • Santa Rosa, California + 12 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more
- Conditions
- Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma
- Interventions
- medical chart review, questionnaire administration, management of therapy complications
- Other · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 15
- States / cities
- Palo Alto, California • New Haven, Connecticut • Chicago, Illinois + 11 more
- Conditions
- Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
- Interventions
- MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 4,390 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more
- Conditions
- Raynaud Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Placebo IV infusion, Iloprost Injection, for intravenous use
- Drug
- Lead sponsor
- Civi Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Atherosclerosis, Coronary Artery Disease
- Interventions
- Percutaneous coronary intervention (Promus PREMIER)
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 48 more